Maccura Biotechnology Co.Ltd
SZSE:300463.SZ
14.39 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,548.757 | 2,895.77 | 3,608.412 | 3,980.647 | 3,703.877 | 3,222.956 | 2,685.305 | 1,969.984 | 1,488.781 | 1,065.169 | 934.846 | 779.427 | 606.155 | 521.308 |
| Cost of Revenue
| 1,144.092 | 1,384.206 | 1,651.771 | 1,673.94 | 1,736.392 | 1,552.946 | 1,294.281 | 911.022 | 683.406 | 458.399 | 380.918 | 340.131 | 266.405 | 247.032 |
| Gross Profit
| 1,404.664 | 1,511.563 | 1,956.641 | 2,306.707 | 1,967.485 | 1,670.01 | 1,391.024 | 1,058.961 | 805.374 | 606.771 | 553.928 | 439.296 | 339.75 | 274.276 |
| Gross Profit Ratio
| 0.551 | 0.522 | 0.542 | 0.579 | 0.531 | 0.518 | 0.518 | 0.538 | 0.541 | 0.57 | 0.593 | 0.564 | 0.561 | 0.526 |
| Reseach & Development Expenses
| 323.153 | 324.167 | 273.221 | 207.266 | 202.073 | 140.136 | 108.795 | 88.439 | 73.015 | 53.621 | 43.772 | 28.268 | 18.913 | 0 |
| General & Administrative Expenses
| 45.66 | 62.146 | 44.259 | 64.88 | 53.808 | 43.398 | 40.708 | 34.272 | 20.319 | 15.899 | 94.878 | 74.11 | 55.951 | 51.169 |
| Selling & Marketing Expenses
| 229.472 | 621.555 | 629.865 | 636.435 | 532.608 | 565.049 | 453.339 | 332.056 | 253.246 | 172.591 | 138.96 | 96.567 | 68.039 | 59.188 |
| SG&A
| 275.132 | 844.057 | 674.125 | 701.315 | 586.416 | 608.447 | 494.047 | 366.328 | 273.565 | 188.49 | 233.838 | 170.677 | 123.989 | 110.357 |
| Other Expenses
| 636.414 | 12.195 | 114.368 | 95.26 | 79.822 | 117.391 | -1.567 | -6.361 | -1.284 | 0.735 | -4.689 | -8.183 | -2.058 | 1.23 |
| Operating Expenses
| 1,234.699 | 1,180.418 | 1,061.714 | 1,003.841 | 868.312 | 865.975 | 713.803 | 518.05 | 408.67 | 291.629 | 243.838 | 179.624 | 131.104 | 116.506 |
| Operating Income
| 169.965 | 331.145 | 817.395 | 1,214.066 | 989.69 | 695.838 | 598.247 | 507.998 | 403.045 | 302.32 | 293.001 | 251.877 | 201.819 | 152.736 |
| Operating Income Ratio
| 0.067 | 0.114 | 0.227 | 0.305 | 0.267 | 0.216 | 0.223 | 0.258 | 0.271 | 0.284 | 0.313 | 0.323 | 0.333 | 0.293 |
| Total Other Income Expenses Net
| -45.314 | -25.776 | -28.311 | -26.939 | -19.924 | -2.667 | -1.567 | -6.361 | -0.982 | 0.076 | -11.434 | -9.436 | -8.804 | 1.028 |
| Income Before Tax
| 124.651 | 305.369 | 789.084 | 1,187.128 | 969.766 | 693.171 | 596.68 | 501.637 | 400.683 | 302.397 | 283.911 | 242.442 | 199.265 | 153.763 |
| Income Before Tax Ratio
| 0.049 | 0.105 | 0.219 | 0.298 | 0.262 | 0.215 | 0.222 | 0.255 | 0.269 | 0.284 | 0.304 | 0.311 | 0.329 | 0.295 |
| Income Tax Expense
| 5.887 | 0.69 | 87.687 | 184.879 | 148.411 | 127.489 | 113.761 | 93.194 | 71.793 | 51.434 | 57.7 | 49.286 | 41.056 | 33.118 |
| Net Income
| 126.805 | 312.619 | 708.18 | 956.604 | 793.918 | 525.263 | 444.929 | 374.132 | 312.023 | 251.044 | 226.211 | 193.156 | 158.209 | 120.415 |
| Net Income Ratio
| 0.05 | 0.108 | 0.196 | 0.24 | 0.214 | 0.163 | 0.166 | 0.19 | 0.21 | 0.236 | 0.242 | 0.248 | 0.261 | 0.231 |
| EPS
| 0.21 | 0.51 | 1.17 | 1.73 | 1.43 | 0.95 | 0.8 | 0.67 | 0.56 | 0.45 | 0.51 | 0.43 | 0.36 | 0.27 |
| EPS Diluted
| 0.21 | 0.51 | 1.16 | 1.72 | 1.42 | 0.94 | 0.8 | 0.67 | 0.56 | 0.45 | 0.51 | 0.43 | 0.36 | 0.27 |
| EBITDA
| 483.351 | 651.985 | 1,098.777 | 1,482.601 | 1,243.17 | 915.998 | 765.893 | 615.845 | 479.282 | 363.213 | 333.495 | 278.572 | 221.331 | 157.77 |
| EBITDA Ratio
| 0.19 | 0.225 | 0.305 | 0.372 | 0.336 | 0.284 | 0.285 | 0.313 | 0.322 | 0.341 | 0.357 | 0.357 | 0.365 | 0.303 |